Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
about
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusGeneral health checks in adults for reducing morbidity and mortality from diseaseTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewComparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesInsulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycleDiabetes Drugs and Cardiovascular SafetyComplications and challenges associated with polycystic ovary syndrome: current perspectivesThe contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failureSomething old, something new and something very old: drugs for treating type 2 diabetesInadequate use and regulation of interventions against publication bias decreases their effectiveness: a systematic reviewSystematic reviews to ascertain the safety of diabetes medicationsTop-down proteomics in health and disease: challenges and opportunitiesAfter avandia: the use of antidiabetic drugs in patients with heart failureHuman obesity and endothelium-dependent responsivenessGlycemic control and cardiovascular disease: what's a doctor to do?PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyClinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combinationUpdate on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Current perspectives on cardiovascular outcome trials in diabetesImprovements in the Management of Diabetic NephropathyDipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsCMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivoComparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic reviewRisk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias ToolAmpelopsin Improves Insulin Resistance by Activating PPARγ and Subsequently Up-Regulating FGF21-AMPK Signaling PathwayCardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesA compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative abilityDrugs for the treatment of pediatric type 2 diabetes mellitus and related co-morbidities.Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management.Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrual.Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case StudiesEvaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection.Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis.
P2860
Q22241134-80F57FA6-1DD5-4B4A-8A6C-E3E7545FB4A1Q22241288-1F3CE1C5-2D12-49B8-AA66-ED73F05D89B3Q24186667-51159BCB-7BF8-4B26-B284-9BD0757EA6F9Q24198193-064F8E20-5305-4511-ADC3-BDEEC3284FC4Q24202505-A684CA49-4E25-409A-8500-BD3816179971Q24236456-A81D09BC-FF22-42CD-980E-B61D96986ED1Q24561401-336E0012-74CC-436D-AED1-554FA2F3E655Q24632655-ABFB0487-CB35-4EF5-928E-5E6A8416D82AQ26745509-BA129EE0-7E25-4772-BF9B-FB4A15EA94ABQ26746085-4DC33EBC-AD13-4EC1-B712-0022DADDE89AQ26799566-9EB35F94-A854-4595-8711-8AF902BB1596Q26830372-355D0CF0-5841-4FFF-821C-105596785792Q26865663-84A3B94B-9A12-4E13-AFF1-840A2ECAB591Q26995526-E2328B45-36C7-49F2-BF08-580E0DE8CFA0Q27000766-A2BDFE36-9CBE-4208-928D-08AADE334CEEQ27002139-15F5C60E-4DD3-409B-A335-D0BCDE42CA59Q27021166-C442EF22-CFEE-4771-AAD8-3B9325FC8367Q27021665-2E56714F-8B20-4701-AD11-6D12A82496FCQ27024469-6948EFE0-F81C-43CA-891E-CB37D8DC6789Q27024799-8FFEBC67-CCE8-4C23-BB58-2AE398239DDAQ27026211-4C7819BD-F008-453B-8BA5-32769067A547Q27687851-23A75479-0DC0-43F0-93C6-B848D588B36FQ28066006-D25C0CC7-A2F3-4FCA-8CD0-F58A24AA4406Q28080717-3AA3F133-36F8-43F0-BDCE-B79FEAF54C05Q28238585-208EF3AD-7629-4060-9817-6093B333535DQ28540538-38DFA502-1E5E-486A-8ADD-53E5B5EE9E05Q28540671-519D146F-0164-4396-8B2A-2E7E2B61BBC4Q28551188-C4C7B4A4-3286-46B4-A670-F77252777B8FQ28552475-47C4D788-FD53-4BE1-A4D3-799F1A229E12Q28741419-C3F3B360-4361-4F6F-9EB2-D878EFDEBA15Q28818450-C84F1D08-5B2F-47CF-8799-F690BC3A2F5EQ30241716-962ED67B-2A14-4F3E-96D4-82B4C7C62852Q30248914-9B31F727-6B65-4E4E-A2CF-993A0B9F3E95Q30392979-5BEF2B00-9D6A-400D-9C85-A9C04B0C9F39Q30404697-A2EE8FC3-65FA-48C2-8222-EE18C3B53929Q30588232-11170E53-7B99-4323-8078-EFDD036A442DQ30665207-83F0B170-3EA0-4F33-9E04-460AF603D58FQ30876081-CA5DB8A4-0175-4BC7-A456-5C90ACE56DAFQ31143283-0C216E22-42E5-4655-8FFC-615C5500FCA3Q33687578-A640E178-8569-4F9B-A389-E1CCDF783FDB
P2860
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rosiglitazone revisited: an up ...... and cardiovascular mortality.
@ast
Rosiglitazone revisited: an up ...... and cardiovascular mortality.
@en
Rosiglitazone revisited: an up ...... and cardiovascular mortality.
@nl
type
label
Rosiglitazone revisited: an up ...... and cardiovascular mortality.
@ast
Rosiglitazone revisited: an up ...... and cardiovascular mortality.
@en
Rosiglitazone revisited: an up ...... and cardiovascular mortality.
@nl
prefLabel
Rosiglitazone revisited: an up ...... and cardiovascular mortality.
@ast
Rosiglitazone revisited: an up ...... and cardiovascular mortality.
@en
Rosiglitazone revisited: an up ...... and cardiovascular mortality.
@nl
P921
P1476
Rosiglitazone revisited: an up ...... and cardiovascular mortality.
@en
P2093
Kathy Wolski
Steven E Nissen
P304
P356
10.1001/ARCHINTERNMED.2010.207
P407
P577
2010-07-01T00:00:00Z